Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.51 |
| ▸ | SRC | P12931 | 8/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PREP | P48147 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29007981 | 0.97 | NR1H2 (0.51) | NR1H2SRCCHRM2CHRM1CHRM3 | |
| SCHEMBL30700528 | 0.90 | NR1H2 (0.55) | NR1H2SRCCHRM2CHRM1CHRM3 | |
| SCHEMBL16584744 | 0.90 | NR1H2 (0.55) | NR1H2SRCCHRM2CHRM1CHRM3 | |
| SCHEMBL261611 | 0.90 | NR1H2 (0.55) | NR1H2SRCCHRM2CHRM1CHRM3 | |
| SCHEMBL610130 | 0.90 | NR1H2 (0.55) | NR1H2SRCCHRM2CHRM1CHRM3 | |
| SCHEMBL19390033 | 0.90 | NR1H2 (0.55) | NR1H2SRCCHRM2CHRM1CHRM3 | |
| SCHEMBL13336742 | 0.90 | NR1H2 (0.55) | NR1H2SRCCHRM2CHRM1CHRM3 | |
| SCHEMBL6853781 | 0.85 | NR1H2 (0.48) | NR1H2SRCCHRM2CHRM1CHRM3 | |
| SCHEMBL6853768 | 0.85 | NR1H2 (0.48) | NR1H2SRCCHRM2CHRM1CHRM3 | |
| SCHEMBL21429615 | 0.81 | NR1H2 (0.46) | NR1H2SRCCHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4216946-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116437913-A | Pharmaceutical compounds for treating complement-mediated disorders | 艾其林医药公司 | 2023-07-14 | — | — | CN | disclosed |
| WO-2022066774-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |